EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Bimekizumab in Chinese Patients with Active Non-Radiographic Axial Spondyloarthritis: 52-Week Results from the Phase 3 BE MOBILE 1 Study

Jieruo Gu, Liangjing Lu, Qiang Wang, Xiaobing Wang, Yongjing Cheng, Shengqian Xu, Yi Zhao, Qi Zhu, Xenofon Baraliakos, Matthew A Brown, Atul Deodhar, James Cheng-Chung Wei und 4 weitere

Rheumatology and Therapy · 2026-12 · 13 (6) · 1459-1478

DOI: 10.1007/s40744-026-00875-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rheumatology and Therapy, online erschienen am 23.10.2026. Verfasst von Jieruo Gu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: UCB.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Bimekizumab, a humanised monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, was efficacious and well tolerated to 52 weeks in patients with non-radiographic axial spondyloarthritis (nr-axSpA) in the global phase 3 multicentre study BE MOBILE 1. In this pre-specified analysis, we examine in more detail the efficacy and safety of bimekizumab in the Chinese subpopulation of patients with nr-axSpA from BE MOBILE 1.

Methods

BE MOBILE 1 comprised a 16-week double-blind, placebo-controlled period and 36-week maintenance period. Patients with nr-axSpA were randomised to receive subcutaneous bimekizumab 160 mg every 4 weeks or placebo to week 16; thereafter, all patients received bimekizumab. Here we report efficacy and safety outcomes to week 52 for the Chinese subpopulation. No formal statistical comparisons were made; results should be interpreted as nominal.

Results

Overall, 36/274 patients in BE MOBILE 1 were enrolled in China (bimekizumab-randomised 18; placebo-randomised 18); 32 completed week 52. A greater proportion of bimekizumab- vs placebo-randomised patients achieved Assessment of SpondyloArthritis international Society (ASAS) ≥ 40% response (38.9% vs 22.2%), ASAS partial remission (33.3% vs 11.1%), and Axial Spondyloarthritis Disease Activity Score < 2.1 (77.7% vs 49.7%) at week 16. By week 52, improvements were comparable between bimekizumab-randomised and placebo-randomised patients who had switched to bimekizumab. Similar trends were observed for objective signs of inflammation, spinal pain, physical function, health-related quality of life, and peripheral manifestations. To week 52, treatment-emergent adverse events (TEAEs) occurred in 33 bimekizumab-treated patients (91.7%), with upper respiratory tract infection the most frequent (10 patients [27.8%]). Four patients (11.1%) had serious TEAEs; four had fungal infections (11.1%; all Tinea ). No patients experienced adjudicated inflammatory bowel disease or uveitis.

Conclusions

In patients with nr-axSpA from China, bimekizumab showed rapid and sustained efficacy improvements to week 52 and was well tolerated, consistent with the global patient population. Graphical Abstract is available for this article. Trial Registration ClinicalTrials.gov identifier, NCT03928704. Graphical Abstract

Schlagwörter

Stichwörter der Autor:innen

Autoimmune diseasesAxial spondyloarthritisBiological therapyChinaCytokinesInflammation

Autor:innen und Institutionen

  • Department of Rheumatology, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China.
  • School of Medicine, Renji Hospital, Jiaotong University, Shanghai, China.
  • Department of Rheumatology, Jiangsu Province Hospital, Nanjing, Jiangsu, China.
  • Rheumatology Department, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • National Center for Clinical Laboratories, Beijing Hospital, Dongdan, Beijing, China.
  • Department of Rheumatism and Immunity, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, Anhui, China.

Förderung

  • UCB

Zitieren

APA

Gu, J., Lu, L., Wang, Q., Wang, X., Cheng, Y., Xu, S., Zhao, Y., Zhu, Q., Baraliakos, X., Brown, M. A., Deodhar, A., Wei, J. C., Marten, A., Oortgiesen, M., Vaux, T., & Xu, H. (2026). Bimekizumab in Chinese Patients with Active Non-Radiographic Axial Spondyloarthritis: 52-Week Results from the Phase 3 BE MOBILE 1 Study. Rheumatology and Therapy, 13(6), 1459-1478. https://doi.org/10.1007/s40744-026-00875-w

Vancouver

Gu J, Lu L, Wang Q, Wang X, Cheng Y, Xu S, et al. Bimekizumab in Chinese Patients with Active Non-Radiographic Axial Spondyloarthritis: 52-Week Results from the Phase 3 BE MOBILE 1 Study. Rheumatology and Therapy. 2026;13(6):1459-1478. doi:10.1007/s40744-026-00875-w

BibTeX
@article{Gu2026,
  author = {Gu, Jieruo and Lu, Liangjing and Wang, Qiang and Wang, Xiaobing and Cheng, Yongjing and Xu, Shengqian and Zhao, Yi and Zhu, Qi and Baraliakos, Xenofon and Brown, Matthew A and Deodhar, Atul and Wei, James Cheng-Chung and Marten, Alexander and Oortgiesen, Marga and Vaux, Tom and Xu, Huji},
  title = {Bimekizumab in Chinese Patients with Active Non-Radiographic Axial Spondyloarthritis: 52-Week Results from the Phase 3 BE MOBILE 1 Study},
  journal = {Rheumatology and Therapy},
  year = {2026},
  volume = {13},
  number = {6},
  pages = {1459--1478},
  doi = {10.1007/s40744-026-00875-w}
}
Kostenlos starten →